20.89
0.00
(0.00%)
May 22 - Close
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | - |
| 52 week | 13.00 - 21.29 |
| Open | - |
| Vol / Avg. | 0.00/401,311.00 |
| Mkt cap | 1.47B |
| P/E | 5.94 |
| Div/yield | - |
| EPS | 3.52 |
| Shares | 70.14M |
| Beta | 1.72 |
| Inst. own | 91% |
Events
Aug 12, 2013
Q2 2013 WuXi AppTec Co., Ltd. Earnings Release
May 28, 2013
WuXi AppTec Co., Ltd. at Daiwa Investment Conference - NY
May 20, 2013
WuXi AppTec Co., Ltd. at Deutsche Bank dbAccess Asia Conference
May 14, 2013
Q1 2013 WuXi AppTec Co., Ltd. Earnings Conference Call -
May 6, 2013
Q1 2013 WuXi AppTec Co., Ltd. Earnings Release
Mar 8, 2013
Q4 2012 WuXi AppTec Co., Ltd. Earnings Conference Call -
Mar 6, 2013
Q4 2012 Wuxi Pharmatech (Cayman) Inc Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 18.96% | 17.32% |
| Operating margin | 18.75% | 17.89% |
| EBITD margin | - | 26.73% |
| Return on average assets | 13.37% | 12.31% |
| Return on average equity | 16.99% | 15.98% |
| Employees | 6,817 | - |
| Carbon Disclosure Rating | - | - |
Address
288 Fute Zhong Road Waigaoqiao Free Trade Zone
SHANGHAI, SHA 200131
China
+86-21-50461111 (Phone)
+86-21-50461000 (Fax)
SHANGHAI, SHA 200131
China
+86-21-50461111 (Phone)
+86-21-50461000 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
WuXi PharmaTech (Cayman) Inc., (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in People�s Republic of China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include the world�s pharmaceutical, biotechnology and medical device companies. The Company has added some services, including discovery biology, safety pharmacology, drug metabolism and pharmacokinetics (DMPK), bioanalytical services, manufacturing process R&D, clinical-trial-scale manufacturing, formulation, toxicology and commercial-scale manufacturing. The Company operates in two segments: Laboratory services segment and Manufacturing Services Segment. In October 2011, the Company acquired Abgent, Inc. In October 2011, the Company acquired MedKey Med-Tech Development Co. Ltd. and Jiecheng Med-Tech Development Co. Ltd.
Officers and directors
| Ge Li Ph.D. | Chairman of the Board, Chief Executive Officer | |
| Edward Hu Ph.D. | Chief Financial Officer, Chief Operating Officer | |
| Xiaozhong Liu | Executive Vice President, Director | |
| Shuhui Chen Ph.D. | Chief Scientific Officer | |
| Yifeng Shi | Vice President - Operations and Head of Waigaoqiao Site, Compliance officer, China | |
| Zhaohui Zhang | Vice President - Domestic Marketing, Director | |
| Suhan Tang Ph.D. | Chief Manufacturing Officer | |
| Ning Zhao Ph.D. | Director | |
| Ying Han | Independent Director | |
| Stewart J. Hen | Independent Director |